Payment overview · 2025
General Payments
$640.19
31 reported records · 15 companies
Healthcare provider profile · identity verified
Mashood Sajjad, MD
Allopathic & Osteopathic Physicians|Hospitalist · MESA, AZ · NPI 1669693040
Verified facts
What the public records show
CMS Open Payments records show Mashood Sajjad, MD received $640.19 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $154.42 | 24.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.56 | 21.2% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $50.72 | 7.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.89 | 6.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.00 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.75 | 5.0% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $29.58 | 4.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $28.43 | 4.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.88 | 4.0% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $25.48 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.94 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.39 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.10 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.78 | 2.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.27 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $640.19 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $154.42 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $135.56 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.72 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $132.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $117.07 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $50.72 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.89 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $28.43 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 242 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 55 |
| Losartan Potassium | Losartan Potassium | 165 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 47 |
| Lisinopril | Lisinopril | 115 | 43 |
| Metformin Hcl | Metformin Hcl | 101 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 89 | 32 |
| Furosemide | Furosemide | 86 | 33 |
| Gabapentin | Gabapentin | 82 | 30 |
| Jardiance | Empagliflozin | 79 | 24 |
| Carvedilol | Carvedilol | 78 | 22 |
| Ozempic | Semaglutide | 74 | 22 |
| Omeprazole | Omeprazole | 73 | 24 |
| Eliquis | Apixaban | 68 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 21 |
| Allopurinol | Allopurinol | 65 | 17 |
| Prednisone | Prednisone | 61 | 40 |
| Potassium Chloride | Potassium Chloride | 60 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 59 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 20 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Famotidine | Famotidine | 42 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 18 |
| Mounjaro | Tirzepatide | 39 | 14 |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 28 |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 15 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | 11 |
| Spironolactone | Spironolactone | 31 | 13 |
| Azithromycin | Azithromycin | 30 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | 11 |
| Cefdinir | Cefdinir | 25 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $640.19 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PROCLAIM, QUTENZA, REPATHA, Rybelsus, Senza, TRELEGY ELLIPTA, Vest Therapy Und, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error